AV
Alexandria Venture Investments
Pasadena, California, United StatesFounded 1996
Alexandria Venture Investments focuses on early- to growth-stage companies across life science, agriculture, technology, and sustainability sectors. Their strategy involves making strategic investments and leveraging their parent company's extensive ecosystem to foster innovation and growth within their portfolio.
92% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (41% of deals). Average disclosed round size is $78.5M (across 73 rounds with reported amounts).
Portfolio
76
Fund Size
$1.6B
Top Stage
Series A
Last 12 Mo
14
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
76 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ten63 Therapeutics | Unknown | — | Feb 2026 |
| TTRexBio | Series C | $50M | Jan 2026 |
 Precede Biosciences | Series B | $63.5M | Jan 2026 |
 Recludix Pharma | Unknown | — | Jan 2026 |
| SSolve Therapeutics, Inc. | Series D | $120M | Nov 2025 |
 Accipiter Biosciences | Seed | $12.7M | Nov 2025 |
 Tr1X, Inc. | Unknown | $50M | Oct 2025 |
 Nilo Therapeutics | Series A | $101M | Oct 2025 |
 Crystalys Therapeutics Inc. | Series A | $205M | Sep 2025 |
 Dualitas Therapeutics, Inc. | Series A | $65M | Sep 2025 |
| LLeal Therapeutics, Inc. | Series A | $30M | Aug 2025 |
 ARTBIO | Series B | $132M | Jul 2025 |
| RRemedy Plan Therapeutics | Series A | $18M | May 2025 |
 Hoofprint Biome | Series A | $15M | Apr 2025 |
 Solu Therapeutics | Series A | $41M | Apr 2025 |
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
 Umoja Biopharma | Series C | $100M | Jan 2025 |
| AAutoimmunity BioSolutions | Seed | $2M | Nov 2024 |
 Axonis Therapeutics | Series A | $115M | Oct 2024 |
 Archon Bioscience | Seed | $20M | Oct 2024 |
| LLeal Therapeutics, Inc. | Series B | $45M | Oct 2024 |
 March Biosciences | Series A | $28.4M | Oct 2024 |
 Outpace Bio | Series B | $144M | Aug 2024 |
 Ability Biologics | Seed | $18M | Jun 2024 |
 Lycia Therapeutics, Inc. | Series C | $106.6M | May 2024 |
Page 1 of 4
Top Co-Investors
ARCH Venture Partners17 shared
OrbiMed8 shared
DCVC7 shared
GV (Google Ventures)7 shared
The Column Group7 shared
Casdin Capital7 shared
Sofinnova Partners7 shared
Cormorant Asset Management6 shared
Eli Lilly and Company6 shared
Qatar Investment Authority6 shared
Lux Capital5 shared
Foresite Capital5 shared
Atlas Venture5 shared
Flagship Pioneering5 shared
Polaris Venture Partners5 shared
Janus Henderson Investors4 shared
Newpath Partners4 shared
Surveyor Capital4 shared
Novo Holdings3 shared
Catalio Capital Management3 shared
Last updated: 15 April 2026